EXAS 📈 EXACT Sciences - Overview

Exact Sciences Corporation is a leading provider of cancer screening and diagnostic test products, operating in the United States and internationally. The company's flagship product, Cologuard, is a non-invasive stool-based DNA screening test that detects DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer, offering a convenient and patient-friendly alternative to traditional screening methods. By leveraging its expertise in molecular diagnostics, Exact Sciences has established itself as a key player in the early detection and prevention of colorectal cancer.

In addition to Cologuard, the company's portfolio includes a range of diagnostic tests, such as the Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, and Oncotype DX Colon Recurrence Score Test. These tests are designed to provide valuable insights into the likelihood of cancer recurrence, enabling healthcare professionals to make informed treatment decisions. Furthermore, the OncoExTra Test offers tumor profiling capabilities for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer, helping to identify potential therapeutic targets. The company has also expanded its services to include Covid-19 testing, demonstrating its ability to adapt to emerging healthcare needs.

Exact Sciences Corporation's research and development efforts are focused on enhancing the performance characteristics of the Cologuard test, as well as developing new blood and fluid-based tests. Through strategic partnerships, including license agreements with renowned institutions such as the MAYO Foundation for Medical Education and Research and Johns Hopkins University, the company has access to a wealth of scientific expertise and resources. With a strong foundation in molecular diagnostics and a commitment to innovation, Exact Sciences is well-positioned to drive growth and improve patient outcomes in the field of cancer screening and diagnosis.

As a publicly traded company, Exact Sciences Corporation is listed on the NASDAQ stock exchange under the ticker symbol EXAS. Incorporated in 1995 and headquartered in Madison, Wisconsin, the company has established a significant presence in the biotechnology industry, with a focus on developing and commercializing innovative diagnostic tests. With a web presence at https://www.exactsciences.com, Exact Sciences provides easy access to information on its products, services, and mission to improve healthcare outcomes. The company's common stock is classified under the GICS Sub Industry: Biotechnology, with an ISIN of US30063P1057, providing investors with a unique opportunity to participate in the growth and development of a leading player in the cancer diagnostics market.